Posted: | May 29, 2018 01:54 PM |
---|---|
From: | Representative Marguerite Quinn |
To: | All House members |
Subject: | Cancer Clinical Trial Access for Pennsylvania Patients (TAPP) |
In the near future I plan to introduce legislation to further define and establish a clear difference between what is considered “inducement” (paying a person money including a lump sum or salary payment) for a patient to participate in a cancer clinical trial and the reimbursement of expenses for participating in a clinical trial. Most corporations, foundations and health care providers are cautious to lend support to possible clinical trial patients due to concerns that the FDA and or other federal regulators would view the payments made from those funds as prohibited inducements for patients to receive the health care services provided during clinical trials. A national study in 2015 found that patient households making less than $50,000 annually were almost 30 percent less likely to participate in clinical trials. The costs of direct and indirect financial responsibilities, travel and/or child care, can hinder the ability for someone to take part in a trial who may otherwise be a very good candidate. The Cancer Clinical Trials Resource Guide, published by the National Cancer Institute, notes that financial barriers often prevent individuals with cancer or at high risk of developing cancer from participating in encouraging clinical trials. Approximately every four minutes, one Pennsylvanian will be diagnosed with cancer. Every ten minutes, one will die. I hope you will join me in sponsoring this legislation ensuring all Pennsylvanians continue to benefit from advances achieved through clinical research. |
Introduced as HB2521